TherapeuticsMD Further Strengthens Board with Appointment of New Independent Director - Karen L. Ling Appointed as Independent Director

TherapeuticsMD, Inc. 8-K

TherapeuticsMD Further Strengthens Board

with Appointment of New Independent Director

- Karen L. Ling Appointed as Independent Director -

April 22, 2020 - On behalf of the Board of Directors of TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's

healthcare company, Chairman Tommy G. Thompson today announced the appointment of Karen L. Ling to the Company's Board of

"We are excited to welcome

Karen to the TherapeuticsMD Board of Directors. Karen is an accomplished executive with experience leading the human resources

functions at a variety of companies and has spent the majority of her career in women's health," said former Governor

and Secretary of Health and Human Services, Thompson. "We believe that Karen's skill set will further complement our

Board of Directors and our Company's recent transformation into a commercial organization."

"I'm delighted to be joining

the Board of Directors of TherapeuticsMD. With its mission to improve the health and welfare of women, TherapeuticsMD brings much

needed innovation and investment to the women's healthcare market. This appointment also has special meaning for me. I built

my career at Wyeth, Merck and Allergan when those companies had significant women's healthcare presences," said Ms. Ling.

"With TherapeuticsMD, I join a company dedicated to women's healthcare and developing products with large, undervalued

market opportunities. I look forward to working with the Board and management team."

Ms. Ling is an accomplished human resources

executive with more than 25 years of pharmaceutical experience. Ms. Ling joined American International Group, Inc. (AIG) as its

as Executive Vice President and Chief Human Resources Officer in July 2019 and is responsible for aligning AIG's talent strategy

with the company's long-term strategic, operational and financial objectives. She oversees all aspects of human capital management,

including talent development, talent acquisition, training, compensation and benefits, and diversity and inclusion. Ms. Ling joined

AIG from Allergan plc, where she served as Executive Vice President and Chief Human Resources Officer from 2015 to 2019. Prior

to its acquisition of Allergan, Ms. Ling was Senior Vice President, Human Resources and Chief Human Resources Officer at Actavis

plc. Previously Ms. Ling was Senior Vice President of Human Resources for Merck Global Human Health and Merck Consumer Care. Prior

to that role, she was Vice President of Global Compensation and Benefits at Merck. Prior to its acquisition by Merck, she was Group

Vice President, Global Compensation & Benefits at Schering-Plough. Ms. Ling also spent 14 years at Wyeth in various positions

of increasing responsibility, most recently as Vice President of Employee Benefits and Compensation. Prior to joining Wyeth, she

practiced corporate law with Goldstein and Manello, P.C. in Boston. Ms. Ling holds a J.D. from Boston University School of Law

and a B.A. from Yale University.

As part of the Board's continued

review of its composition and effectiveness, the Board has reduced its size from eleven directors to nine directors. In connection

with this reduction in size, directors Robert V. LaPenta, Jr. and Jane Barlow, M.D. agreed to resign from the Board, effective

April 16, 2020. Following the appointment of Ms. Ling, the Company's Board of Directors consists of nine members with no

In connection with Mr. LaPenta,

Jr.'s resignation, Mr. Angus C. Russell was appointed as the Chairman of the Company's Audit Committee and Mr. Paul

M. Bisaro was appointed as a member of the Audit Committee.

"Our Board of Directors

has determined that this is the right time to reduce the size of the Board to nine members. As a result of and in support of

this action, Rob LaPenta and Jane Barlow have decided to resign from the Board now in advance of the Company's 2020

Annual Meeting of Stockholders. The Board and I would like to thank Rob and Jane for their service and contributions to the

Company. Rob joined the Board in 2012 and was an integral advisor on financial matters during our drug development process.

Jane has provided invaluable guidance to the Company during its three commercial launches," said former Governor and

Secretary of Health and Human Services Thompson. "We wish Rob and Jane well in their future endeavors and are happy

that both have agreed to remain advisors to the Company."

About TherapeuticsMD

TherapeuticsMD, Inc. is an innovative,

leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed

to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus

in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and

championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or

Forward-Looking Statements

This press release by TherapeuticsMD,

Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating

to TherapeuticsMD's objectives, plans and strategies as well as statements, other than historical facts, that address activities,

events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These

statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates,"

"should," "intends," "plans," "will," "expects," "estimates," "projects,"

"positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light

of management's experience and perception of historical trends, current conditions, expected future developments and other

factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release,

and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events

or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties,

many of which are outside of the company's control. Important factors that could cause actual results, developments and

business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors"

in the company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K

and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic;

the company's ability to maintain or increase sales of its products; the company's ability to develop and commercialize

IMVEXXY , ANNOVERA , BIJUVA and its hormone therapy drug candidates and obtain additional financing necessary therefor;

whether the company will be able to comply with the covenants and conditions under its term loan facility, including the conditions

to draw an additional tranche thereunder and whether the lender will make such tranche available; the potential of adverse side

effects or other safety risks that could adversely affect the commercialization of the company's current or future approved

products or preclude the approval of the company's future drug candidates; whether the FDA will approve the efficacy supplement

for the lower dose of BIJUVA; the company's ability to protect its intellectual property, including with respect to the

Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future

clinical trials; the company's reliance on third parties to conduct its manufacturing, research and development and clinical

trials; the ability of the company's licensees to commercialize and distribute the company's products; the ability

of the company's marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities

and health insurance companies for the company's products; the impact of product liability lawsuits; the influence of extensive

and costly government regulation; the volatility of the trading price of the company's common stock and the concentration

of power in its stock ownership. PDF copies of the company's historical press releases and financial tables can be viewed

and downloaded at it website: www.therapeuticsmd.com/pressreleases.aspx.

Vice President, Investor Relations

561-961-1900, ext. 2088